Target-Specific Imaging Agents Ushering in New Opportunities for Detecting and Mapping Neurology Dis

Applied Data Research Analyzes the Potential of Evolving Contrast Agents in the Imaging of Neurological Structures and Diseases.

[USPRwire, Wed Sep 29 2010] A new generation of imaging agents that can target specific organs and even specific molecules is poised to play a pivotal role in the advancement of disease detection and metabolic process mapping. The ability of this new generation of contrast agents to detect changes at the molecular level has significant potential for improving visualization and quality of care. One of the most promising areas for this new technology is in neurological imaging.

These agents possess a unique capability to generate unambiguous images by exploiting specific molecular targets, pathways or cellular processes. From amyloid plaques and Parkinson’s to psychiatric disorders and pathologies of the peripheral nervous system, the ability of imaging diagnostics to detect abnormalities, monitor therapeutic outcomes, guide interventional procedures and play an active role in disease therapies is positioned to increase dramatically.

The market impact of targeted agents for key neurological diagnostic applications extends to a range of specific neurology targets and includes Ach, D1/D4 dopamine receptors, amyloidosis group proteins, SERT, 5-HT, CB1, adenosine and NK1. As clinicians continue to refine diagnostic protocols and procedures, the experiential migration of target-specific neurology imaging will result in improved morbidity and mortality outcomes for affected patient populations.

These findings are contained in a new and comprehensive report. Target-Specific Neurology Imaging Agents: Evolving Applications, Emerging Opportunities contains in-depth analysis of the science, technology, clinical applications and market participants shaping the neurological diagnostic imaging space.

More information is also available at www.applieddata.org .

About Applied Data

Applied Data Research is a healthcare technology consulting firm focused on market strategies, product commercialization, venture development, and market research. We assist market participants in achieving their business objectives through the creation of detailed business development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Because we make it our responsibility to cut through the clutter and the noise of modern information gathering and assessment, company decision makers turn to us for the answers they need to achieve their objectives.

Contact:

Greg Stone
Voice: 603-595-6225
www.applieddata.org

Source: Applied Data Research